Core Viewpoint - In 2024, Chuangmei Pharmaceutical achieved significant growth in revenue and net profit, driven by the dual forces of policy deepening and digital transformation in the Chinese pharmaceutical distribution industry, alongside an expanding retail market and diversified services [1][2]. Financial Performance - For the year ending December 31, 2024, Chuangmei Pharmaceutical reported a revenue of RMB 4.435 billion and a net profit of RMB 53.28 million, both showing year-on-year growth compared to 2023 [1]. - The basic and diluted earnings per share increased to RMB 0.4934, with a proposed final dividend of RMB 0.45 per share, representing a high payout ratio of 91% [1]. Business Development - The company established a comprehensive industrial chain and commercial ecosystem by collaborating with well-known pharmaceutical companies such as China Resources Sanjiu, Helion, and Guangzhou Pharmaceutical Baiyunshan [2]. - As of December 31, 2024, Chuangmei Pharmaceutical distributed 12,810 products through a network covering 14,429 customers, with 1,206 suppliers, all showing stable growth from 2023 [2]. Logistics and Supply Chain - The company launched a new pharmaceutical logistics center in Shenzhen, enhancing multi-warehouse collaboration and cross-regional distribution, which reduced logistics costs and ensured drug quality [3]. - Chuangmei Pharmaceutical's third-party logistics business saw a 30% increase in customer numbers and over 55% growth in related revenue, marking a significant milestone in its logistics operations [3]. Technological Innovation - The company is exploring AI applications in business processes, achieving partial automation and establishing an intelligent workflow engine to enhance operational efficiency [4]. - Future plans include a comprehensive digital integration of processes, leveraging AI for resource optimization and decision-making, thereby enhancing overall operational effectiveness and core competitiveness [4]. Strategic Outlook - Chuangmei Pharmaceutical aims to deepen its market presence in Guangdong and surrounding areas, aspiring to become a leading competitive player in the pharmaceutical health services sector in China [4]. - The company plans to capitalize on digital and intelligent transformation opportunities in the pharmaceutical industry, focusing on AI technology integration and expanding its product offerings through strategic partnerships [4].
创美药业2024年营收和净利润实现双增长 全年派息比例达91%